TPMT and acute lymphoblastic leukemia: Based on these studies, CPIC in 2018 updated its guidelines for the dosage adjustment of 6-MP, suggesting that ALL patients should be guided by TPMT and NUDT15 genotyping for the initial dose selection of 6-MP (Relling et al., 2019).